Evidence brief
BPC-157
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
Still being studied; no FDA-approved BPC-157 product identified.
Cell and animal studies, plus small early studies in people, do not prove that BPC-157 heals injuries in people.
- How strong is the evidence?
- Emerging
Some studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation. - What evidence exists?
- Investigational human outcomes
Studies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain. - Sports rules
- Prohibited
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as BPC 157 · Body Protection Compound 157 · pentadecapeptide BPC 157
Part of Healing and recovery peptides
Compared with TB-500
Words used here
- investigational
- still being studied and not approved for that use
- outcome
- what the study measured
- molecule
- one specific chemical substance
- peptide
- a short chain of amino acids
- preclinical
- research in cells, tissues, or animals before or outside testing in people
- amino acid
- a small building block that makes peptides and proteins
- indication
- the approved or studied use and patient group
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Small uncontrolled pilots cannot establish a patient benefit.
Human exposure and pharmacokinetic characterization remain sparse.
The human safety dataset is too small for confident risk estimates.
No validated approved formulation; identity and purity vary outside formal research.
02 · Identity
What it is
Online popularity is not proof that a treatment works. BPC-157 is a synthetic 15-amino-acid peptide promoted online for injury recovery and other uses. Popularity, testimonials, animal findings, and availability are not evidence of an approved or proven human treatment.
Scientific group: Synthetic pentadecapeptide. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
None identified in the United States.
- No FDA-approved indication
04 · Research results
What the research shows
The preclinical literature contains positive signals in cell and animal models, including tendon-healing models. Small human pilot work and registered clinical research now exist, but do not establish a clinical effect in people. FDA's July 2026 PCAC briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. That advisory-stage record supports scrutiny; it is not a final FDA determination.
The available evidence still does not establish that BPC-157 safely heals sports injuries or other conditions in people. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
Exact product
A peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial are separate evidence objects. Identity and product quality cannot be assumed from the name.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“BPC-157 improves tendon healing in preclinical models.”
Cell and rat tendon studies report positive healing signals. The scope matters: these results support biological plausibility, not a proven human treatment.
- Evidence used
- Preclinical evidence. This answer uses research in cells, animals, or other settings outside patient care. It does not show a benefit in people.
- Limits of this answer
- Cell and animal tendon models only; not clinical healing outcomes in people. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“BPC-157 heals tendons and muscles in people.”
Early human work is too small and limited to establish efficacy. Reliable, replicated human outcome evidence is still needed.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Human tendon and muscle-healing claims; existing pilots and a trial registration do not establish benefit. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Athletes can use it because it is not a steroid.”
The 2026 WADA Prohibited List places BPC-157 in S0 non-approved substances, which is prohibited at all times for covered athletes. Whether it is a steroid is irrelevant to that status.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Athletes subject to the current WADA Code and their applicable governing-body rules. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about BPC-157
Still being studied; no FDA-approved BPC-157 product identified. No approved product is identified in the United States.
Prohibited. BPC-157 is listed under WADA's S0 non-approved substances category and is prohibited at all times for covered athletes. This status is not personal clearance to compete.
The preclinical literature contains positive signals in cell and animal models, including tendon-healing models. Small human pilot work and registered clinical research now exist, but do not establish a clinical effect in people. FDA's July 2026 PCAC briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. That advisory-stage record supports scrutiny; it is not a final FDA determination.
The available evidence still does not establish that BPC-157 safely heals sports injuries or other conditions in people. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
07 · Safety
Safety limits for this record
The site will not provide self-injection, reconstitution, dosing, sourcing, or stack instructions. “Research use only” does not establish quality or make a product appropriate for human use.
BPC-157 is listed under WADA's S0 non-approved substances category and is prohibited at all times for covered athletes.
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed .Check current rules for tested sport ↗Open the governing record ↗08 · Sources
Read the sources
09 · Review history
Review history
Revalidated BPC-157's S0 prohibited-at-all-times status against the 2026 WADA Prohibited List.
Updated around FDA's July 2026 briefing and explicit product-identity boundaries.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.